Literature DB >> 32523147

Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19.

Luis M Amezcua-Guerra1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32523147     DOI： 10.24875/ACM.M20000067

Source DB:  PubMed          Journal:  Arch Cardiol Mex        ISSN： 1665-1731


× No keyword cloud information.
  4 in total

1.  A simple and readily available inflammation-based risk scoring system on admission predicts the need for mechanical ventilation in patients with COVID-19.

Authors:  Luis M Amezcua-Guerra; Karen Audelo; Juan Guzmán; Diana Santiago; Julieta González-Flores; Carlos García-Ávila; Zaira Torres; Francisco Baranda-Tovar; Claudia Tavera-Alonso; Julio Sandoval; Héctor González-Pacheco
Journal:  Inflamm Res       Date:  2021-05-10       Impact factor: 4.575

2.  Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients.

Authors:  Lili Li; Jie Li; Meiling Gao; Huimin Fan; Yanan Wang; Xin Xu; Chunfeng Chen; Junxiao Liu; Jocelyn Kim; Roghiyh Aliyari; Jicai Zhang; Yujie Jin; Xiaorong Li; Feng Ma; Minxin Shi; Genhong Cheng; Heng Yang
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 3.  Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19?

Authors:  Diana Castillo-Martínez; Zaira Torres; Luis M Amezcua-Guerra; Carlos Pineda
Journal:  Clin Rheumatol       Date:  2021-04-07       Impact factor: 2.980

4.  Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study.

Authors:  Rashidi Springall; Julieta González-Flores; Carlos García-Ávila; Yaneli Juárez-Vicuña; Adrián Hernández-Diazcouder; Ricardo Márquez-Velasco; Sergio Cásares-Alvarado; Fausto Sánchez-Muñoz; Edna Basilio-Gálvez; Mauricio Castillo-Salazar; Martha A Ballinas-Verdugo; Malinalli Brianza-Padilla; José L Sánchez-Gloria; Claudia Tavera-Alonso; Julio Sandoval; Héctor González-Pacheco; Luis M Amezcua-Guerra
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-08-03       Impact factor: 3.831
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.